Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a modified analogue of human GLP-1 with 94% sequence homology. The modifications include a C18 fatty diacid chain attached via a linker to lysine at position 34, which enables albumin binding and extends the half-life significantly compared to native GLP-1.
Mechanism
Semaglutide binds to and activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Its extended half-life (approximately 7 days in clinical use) is achieved through albumin binding via its fatty acid side chain.
Research Areas
-
Metabolic Research
Widely studied for its role in glucose homeostasis, insulin secretion, and glucagon suppression in metabolic research models.
-
Appetite & Satiety Research
Research has examined GLP-1 receptor signaling in appetite regulation centers in the hypothalamus and brainstem.
-
Cardiovascular Research
Studies have explored GLP-1 receptor agonism and its effects on cardiovascular endpoints in preclinical models.
-
Neuroprotection Research
Emerging research examines GLP-1 receptor expression in the brain and potential neuroprotective mechanisms.
Storage
Store lyophilized at -20°C. Reconstitute with sterile water. Stable at 4°C for up to 28 days once reconstituted.